The White House has denied reports that the government could soon ban COVID-19 vaccines, noting that in the absence of an ...

The MIT professor of management, who already sits on the CDC's revamped immunization advisory committee, is a known skeptic ...

As the political winds shift on a whim and public distrust of the pharma industry reaches fever pitch over drug pricing, ...

If the trend holds, IQVIA expects 2025 deal volume between Chinese and multinational companies to easily eclipse the 100 ...

Scott Gottlieb, who served as FDA commissioner during the first Trump administration, wrote in a JAMA editorial that China is ...

Health Secretary Robert F. Kennedy Jr. will testify before the Senate Finance Committee on Sept. 4, following the ouster of CDC Director Susan Monarez and tapping of HHS Deputy Secretary Jim O’Neill ...

Nipocalimab, approved as Imaavy for generalized myasthenia gravis earlier this year, failed to show significantly added benefit when used with an anti-TNFα therapy in patients with rheumatoid ...

Regeneron’s cemdisiran, used alone or in combination with its complement inhibitor Veopoz, significantly improved activities ...

Appia Bio's shutdown continues an unfortunate trend this year that has seen biotech closures nearly every month.

Generate:Biomedicines’ Nicole Clouse is one of the key legal minds trying to understand who owns what AI creates. The answers ...

While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition," they also pointed to ...

The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...